多发性骨髓瘤患者自体干细胞移植后微小残留病:预后意义及来那度胺维持治疗与分子风险的影响
基于Myeloma XI III期试验数据,分析自体干细胞移植后3个月和9个月微小残留病(MRD)状态与无进展生存期(PFS)和总生存期(OS)的关系。移植后3个月MRD阴性475/750例(63.3%),与PFS改善(HR=0.47)和OS改善(HR=0.59)相关;移植后9个月MRD阴性214/326例(65.6%),与PFS改善(HR=0.20)和OS改善(HR=0.33)相关。来那度胺维持治疗组从MRD阳性转为阴性的比例高于观察组(30% vs 17%)。
要点
- 移植后3个月MRD阴性率63.3%,与PFS(HR=0.47)和OS(HR=0.59)改善相关。
- 移植后9个月MRD阴性率65.6%,与PFS(HR=0.20)和OS(HR=0.33)改善相关。
- 来那度胺维持组MRD阳性转阴性比例30%,观察组17%。
核心结论
- 在多发性骨髓瘤患者中,自体干细胞移植后3个月和9个月的MRD状态均是PFS和OS的强预测因素。
研究设计与样本
- 基于大型III期试验(Myeloma XI)数据,分析移植后3个月随机分配到来那度胺维持或无维持治疗患者的MRD状态与PFS和OS的关系。
- MRD状态通过流式细胞术评估(中位灵敏度0.004%),分别在维持治疗随机分配前(移植后3个月)和6个月后(移植后9个月)进行检测。
主要发现
- 移植后3个月,475/750例(63.3%)患者为MRD阴性,275例(36.7%)为MRD阳性;MRD阴性状态与PFS改善(HR=0.47;95%CI 0.37-0.58;P<.001)和OS改善(HR=0.59;95%CI 0.40-0.85;P=.0046)相关。
- 移植后9个月,214/326例(65.6%)为MRD阴性,112例(34.4%)为MRD阳性;MRD阴性状态与PFS改善(HR=0.20;95%CI 0.13-0.31;P<.0001)和OS改善(HR=0.33;95%CI 0.15-0.75;P=.0077)相关。
- 从移植后3个月到9个月持续MRD阴性或在移植后9个月时转为MRD阴性的患者PFS/OS最长。
- 随机分配到来那度胺维持治疗的患者从维持前MRD阳性转为6个月后MRD阴性的比例高于观察组(来那度胺30% vs 观察17%)。
- 高危分子特征对即使达到MRD阴性状态患者的PFS和OS仍有不良影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Minimal residual disease (MRD) can predict outcomes in patients with multiple myeloma, but limited data are available on the prognostic impact of MRD when assessed at serial time points in the context of maintenance therapy after autologous stem-cell transplant (ASCT) and the interaction between MRD and molecular risk. METHODS: Data from a large phase III trial (Myeloma XI) were examined to determine the relationship between MRD status, progression-free survival (PFS), and overall survival (OS) in post-ASCT patients randomly assigned to lenalidomide maintenance or no maintenance at 3 months after ASCT. MRD status was assessed by flow cytometry (median sensitivity 0.004%) before maintenance random assignment (ASCT + 3) and 6 months later (ASCT + 9). RESULTS: At ASCT + 3, 475 of 750 (63.3%) patients were MRD-negative and 275 (36.7%) were MRD-positive. MRD-negative status was associated with improved PFS (hazard ratio [HR] = 0.47; 95% CI, 0.37 to 0.58 P < .001) and OS (HR = 0.59; 95% CI, 0.40 to 0.85; P = .0046). At ASCT + 9, 214 of 326 (65.6%) were MRD-negative and 112 (34.4%) were MRD-positive. MRD-negative status was associated with improved PFS (HR = 0.20; 95% CI, 0.13 to 0.31; P < .0001) and OS (HR = 0.33; 95% CI, 0.15 to 0.75; P = .0077). The findings were very similar when restricted to patients with complete response/near complete response. Sustained MRD negativity from ASCT + 3 to ASCT + 9 or the conversion to MRD negativity by ASCT + 9 was associated with the longest PFS/OS. Patients randomly assigned to lenalidomide maintenance were more likely to convert from being MRD-positive before maintenance random assignment to MRD-negative 6 months later (lenalidomide 30%, observation 17%). High-risk molecular features had an adverse effect on PFS and OS even for those patients achieving MRD-negative status. On multivariable analysis of MRD status, maintenance therapy and molecular risk maintained prognostic impact at both ASCT + 3 and ASCT + 9. CONCLUSION: In patients with multiple myeloma, MRD status at both ASCT + 3 and ASCT + 9 is a powerful predictor of PFS and OS.
引用
- de Tute RM, Pawlyn C, Cairns DA, et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. J Clin Oncol. 2022. PMID: 35377708. doi:10.1200/JCO.21.02228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。